Literature DB >> 16883348

Treatment options for the eradication of intestinal protozoa.

Michael J G Farthing1.   

Abstract

Pathogenic intestinal protozoa are responsible for clinically important infections in both the developed and the developing world. These organisms are responsible for both acute and chronic diarrhea, and Entamoeba histolytica, which affects the colon, can spread to involve the liver. Many of these pathogens, particularly the intracellular protozoa that predominantly affect the small intestine, produce their most devastating effects in patients with HIV/AIDS and other forms of immune deficiency. There are also various intestinal protozoa that do not seem to have any adverse effects on humans and can, therefore, be regarded as harmless commensal organisms. Although treatment has been available for several decades for giardiasis, isosporiasis and amoebiasis, until recently there have been no effective remedies for infection with intestinal coccidia--Cryptosporidium, Microsporidium and Cyclospora species. Cyclospora respond well to co-trimoxazole, microsporidia respond variably to albendazole, and cryptosporidia can often be eradicated by nitazoxanide. In chronically infected HIV-positive patients, treatment with multidrug regimens usually results in rapid resolution of the diarrhea and, in many instances, eradication of the parasite.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16883348     DOI: 10.1038/ncpgasthep0557

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  27 in total

1.  Co-infection with Cyclospora cayetanensis and Salmonella typhi in a patient with HIV infection and chronic diarrhoea.

Authors:  Rafael Llanes; Beltran Velázquez; Zoila Reyes; Lorenzo Somarriba
Journal:  Pathog Glob Health       Date:  2013-01       Impact factor: 2.894

2.  Development of metronidazole-resistant lines of Blastocystis sp.

Authors:  L A Dunn; K S W Tan; P Vanelle; T Juspin; M D Crozet; T Terme; P Upcroft; J A Upcroft
Journal:  Parasitol Res       Date:  2012-02-24       Impact factor: 2.289

Review 3.  Recent advances in small bowel diseases: Part I.

Authors:  Alan B R Thomson; Angeli Chopra; Michael Tom Clandinin; Hugh Freeman
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

Review 4.  Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections.

Authors:  Jaco J Verweij; C Rune Stensvold
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 5.  The first 1000 cultured species of the human gastrointestinal microbiota.

Authors:  Mirjana Rajilić-Stojanović; Willem M de Vos
Journal:  FEMS Microbiol Rev       Date:  2014-06-27       Impact factor: 16.408

6.  Mucosal microbial parasites/symbionts in health and disease: an integrative overview.

Authors:  Robert P Hirt
Journal:  Parasitology       Date:  2019-08       Impact factor: 3.234

7.  An unusual complication in ulcerative colitis during treatment with azathioprine and infliximab: Isospora belli as 'Casus belli'.

Authors:  Juergen Stein; Egbert Tannich; Franz Hartmann
Journal:  BMJ Case Rep       Date:  2013-05-24

Review 8.  Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.

Authors:  Vanessa R Anderson; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Clinical significance of enteric protozoa in the immunosuppressed human population.

Authors:  D Stark; J L N Barratt; S van Hal; D Marriott; J Harkness; J T Ellis
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  Dietary supplementation of mannan-oligosaccharide enhances neonatal immune responses in chickens during natural exposure to Eimeria spp.

Authors:  Gabriela Gómez-Verduzco; Arturo Cortes-Cuevas; Carlos López-Coello; Ernesto Avila-González; Gerardo M Nava
Journal:  Acta Vet Scand       Date:  2009-03-19       Impact factor: 1.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.